Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial
Anita Afzali, Silvio Danese, Remo Panaccione, David T Rubin et autres
us, it, ca, at, es, jp, au, nl (code pays fourni par la source)